TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05509387

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial direct current stimulation and naming training
Description: Participants will receive mild stimulation or no stimulation along with naming training

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation and naming training
Description: Participants will receive mild stimulation or no stimulation along with naming training

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial direct current stimulation and naming training
Description: Participants will receive mild stimulation or no stimulation along with naming training
Study: NCT05433155

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasotracheal intubation
Description: Nontracheal intubation using clinical standard videolaryngoscopy or direct laryngoscopy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasotracheal intubation
Description: Nontracheal intubation using clinical standard videolaryngoscopy or direct laryngoscopy
Study: NCT05859074

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MQ719
Description: Patients will receive either multidose monotherapy with MQ710 or multidose combination therapy with MQ710 and pembrolizumab. The applicable dose of MQ710 will be injected directly into the patient's tumor (intratumorally), and standard dosing of pembrolizumab (200 mg) will be administered intravenously at a 3-week interval.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MQ719
Description: Patients will receive either multidose monotherapy with MQ710 or multidose combination therapy with MQ710 and pembrolizumab. The applicable dose of MQ710 will be injected directly into the patient's tumor (intratumorally), and standard dosing of pembrolizumab (200 mg) will be administered intravenously at a 3-week interval.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Patients will receive either multidose monotherapy with MQ710 or multidose combination therapy with MQ710 and pembrolizumab. The applicable dose of MQ710 will be injected directly into the patient's tumor (intratumorally), and standard dosing of pembrolizumab (200 mg) will be administered intravenously at a 3-week interval.
Study: NCT06419088

Intervention type: OTHER
Group type: OTHER
Intervention: Preoperative individualized education
Description: Based on the identified individual education needs, the researcher implemented audio-visual education to the intervention group in the ward.
Study: NCT06353906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin/Paclitaxel
Description: Induction: three cycles of intravenous carboplatin AUC5 (max 750 mg) and paclitaxel 175 mg/m2, during cycle 1, 2 and 3 (day 1, 22, 43)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Induction: two cycles of intravenous pembrolizumab 400 mg during cycle 1 and 3 (day 1 and 43)~Adjuvant: up to seven cycles of fixed-dose intravenous pembrolizumab 400 mg, on day 1 every 6 weeks within 3-9 weeks after surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Partial or total penectomy with inguinal and/or pelvic lymph node dissection
Description: Resection of part or all of the penis with complete removal of suspect lymphnodes in the inguinal and/or pelvic area
Study: NCT06451991

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Use of concept map in clinical practice in nursing students
Description: Concept map will be used in clinical practice in nursing students.
Study: NCT06259331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPN-812 (600mg, QD)
Description: Viloxazine ER
Study: NCT04703452

Intervention type: OTHER
Intervention: Indicators of central sensitisation
Description: Indicators of central sensitisation, assessed by the Central Sensitization Inventory
Study: NCT06447844

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OsteoGen Plug
Description: OsteoGen® Plug is contoured to fill the three roots of the socket. Plug is delivered dry into a thoroughly debrided and actively bleeding socket. The OsteoGen® Plug is condensed firmly into the socket.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BioGide
Description: BioGide is a resorbable collagen membrane
Study: NCT05682131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Realgar Indigo naturalis formula
Description: Realgar Indigo naturalis formula was used in the induction, consolidation and intensive treatment of patients in intermediate or high risk

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Conventional chemotherapy
Description: conventional chemotherapy

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Conventional chemotherapy
Description: conventional chemotherapy
Study: NCT03634553

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training with e-health product
Description: The training program follows the recommendations for training from ACSMS and SoS who states the importance that exercise programs should include muscle strengthening, cardiovascular as wells as balance exercises. Therefore, the training program includes: Strengthening exercises for the upper and lower extremities (number: 5-8 pc. with progression in three levels), daily (5-7 times / week), 30 minutes walks and balance training.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: usual care, i.e. participates in regular training regime at the physiotherapy department
Study: NCT04907032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron 50 MG
Description: Posterior Tibial Nerve Stimulation with Mirabegron vs. Posterior Tibial Nerve Stimulation Plus Placebo

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Posterior Tibial Nerve Stimulation (PTNS)
Description: Posterior Tibial Nerve Stimulation with Mirabegron vs. Posterior Tibial Nerve Stimulation Plus Placebo

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Posterior Tibial Nerve Stimulation (PTNS)
Description: Posterior Tibial Nerve Stimulation with Mirabegron vs. Posterior Tibial Nerve Stimulation Plus Placebo
Study: NCT05281614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Etanercept is a fully humanized monoclonal antibody that targets TNFα.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Description: Vedolizumab is a humanized monoclonal antibody that targets α4ß7 integrin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Description: Vedolizumab is a humanized monoclonal antibody that targets α4ß7 integrin.
Study: NCT05675553

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: robot-assisted rehabilitation intelligent treatment
Description: Participants assigned to this condition were offered 10 individual sessions of robot-assisted rehabilitation treatment, delivered by the Robot-assisted rehabilitation intelligent system. The system contains 10 core cognitive-behavioral therapy (CBT) skill topics (such as functional analysis, coping skills training, reviewing practice exercises, and explaining CBT concepts). A robot therapist demonstrates the target CBT skills and assigns homework to participants. The treatment framework is semi-structured through human-computer interaction. The forms of interaction include inquiries, statements, recommendations summaries, and knowledge assessments.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: treatment as usual
Description: Both groups will receive treatment as usual, including medication, exercise, and psychological education.

Intervention type: OTHER
Group type: OTHER
Intervention: treatment as usual
Description: Both groups will receive treatment as usual, including medication, exercise, and psychological education.
Study: NCT05756686

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breathing Group 1
Description: The 8-week breathwork intervention incorporates a set of breathing practices under the guidance of a certified yoga teacher.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Breathing Group 2
Description: The 8-week breathwork intervention incorporates a set of slow breathing practices under the guidance of a certified yoga teacher.
Study: NCT05206474

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IRADYN
Description: One course of IRADYN® at baseline, consisting of a mono-dose intra-articular administration (2 ml).~From week 1 to week 6, injection will be performed, if necessary, during the visit, following the dosage reported in the instruction for use / summary of product characteristic.
Study: NCT05415722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TERN-501
Description: Investigational drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TERN-501
Description: Investigational drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TERN-501
Description: Investigational drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TERN-501
Description: Investigational drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TERN-501
Description: Investigational drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TERN-101
Description: Investigational drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TERN-101
Description: Investigational drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TERN-101
Description: Investigational drug

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study: NCT05741866

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate impregnated bordered polyurethane dressing
Description: PIVCs will be dressed and secured at the participating sites~* RBWH and PUH: PIVCs will be dressed with Tegaderm™ Antimicrobial I.V. Advanced Securement (9132) dressing and secured with non-sterile tape over extension tubing.~* QCH: PIVCs will be dressed with Tegaderm™ Antimicrobial I.V. Advanced Securement (9132) dressing and secured with tubular bandage +/- arm board and non-sterile stretchy tape if PIVC over flexible joint, +/- tissue adhesive as per clinician preference.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard bordered polyurethane dressing
Description: PIVCs will be dressed and secured as per standard practice at the participating sites~* RBWH and PUH: Bordered polyurethane dressing (Tegaderm™ IV Advanced 1683) and non-sterile tape strip over extension tubing.~* QCH: Bordered polyurethane dressing (Tegaderm™ IV Advanced 1682 or 1683) and secured with tubular bandage +/- arm board and non-sterile stretchy tape if PIVC over flexible joint, +/- tissue adhesive as per clinician preference.
Study: NCT04789616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: Half of the participants will take maraviroc for a period of 8 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Program
Description: All participants will take part in an 8-week exercise program. While in-hospital, participants will undergo standard of care rehabilitation (estimated at 45 minutes each daily for physiotherapy \& occupational therapy) plus a supplementary upper extremity exercise program (Graded Repetitive Arm Supplementary Program (GRASP); estimated at 1 hour daily).~After discharge from inpatient care, participants will complete an at-home supplementary upper and lower extremity exercise program. This program will include 30 minutes daily walking or sit-to-stand exercises and 30 minutes daily practice using the GRASP program.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Exercise Program
Description: All participants will take part in an 8-week exercise program. While in-hospital, participants will undergo standard of care rehabilitation (estimated at 45 minutes each daily for physiotherapy \& occupational therapy) plus a supplementary upper extremity exercise program (Graded Repetitive Arm Supplementary Program (GRASP); estimated at 1 hour daily).~After discharge from inpatient care, participants will complete an at-home supplementary upper and lower extremity exercise program. This program will include 30 minutes daily walking or sit-to-stand exercises and 30 minutes daily practice using the GRASP program.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Half of the participants will take a placebo for a period of 8 weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Activity Sensor
Description: Participants will be asked to wear small activity sensors (one on each wrist and one on each ankle, total of four sensors) at the baseline, 4-week, 8-week, and 6-month assessments for 7 consecutive days. Activity related to walking, sleep, physical activity, and arm and leg movement throughout the day will be measured.~The sensors will be worn for a total of 28 days throughout the study.
Study: NCT04817410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emergency Department Initiated Oral Naltrexone
Description: Emergency Department Initiated Oral Naltrexone
Study: NCT05942742

Intervention type: DEVICE
Intervention: MRI Linac
Description: External radiotherapy will be performed at Linac MRI, 25 fractions of radiation will be delivered for each patient.The MR-linac offers the ability to individualise and adapt daily treatment plans based on the position or anatomy of the day, following either a simple 'virtual couch shift' adapt-to-position (ATP) approach, or a more complex full reoptimisation adapt-to-shape (ATS) method based on the recontouring of relevant structures. During each radiation therapy, T2-weighted images and diffusion images will be purchased.Treatment plans can be produced and checked by appropriately trained Radiation Oncologists. Each radiation oncologist will decide based on the anatomy of the day the type of workflow to be used (ADP or ATS) for treatment.Patients will undergo accurate image acquisition, registration and interpretation to make sound clinical judgements and proceed to safe and accurate treatment delivery.
Study: NCT04717986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10Mg Tab
Description: patients who meet the inclusion criteria will be randomized to receive dapagliflozin 10 mg every 24 hours for 12 months
Study: NCT05473494

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: training group
Description: Trainings on diabetic foot care consisting of min 20 max 40 minutes will be given in 5 sessions for nine weeks. Training will be given face to face online.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control group
Description: Group not to be trained.
Study: NCT04789616

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Activity Sensor
Description: Participants will be asked to wear small activity sensors (one on each wrist and one on each ankle, total of four sensors) at the baseline, 4-week, 8-week, and 6-month assessments for 7 consecutive days. Activity related to walking, sleep, physical activity, and arm and leg movement throughout the day will be measured.~The sensors will be worn for a total of 28 days throughout the study.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor Learning
Description: Participants will be asked to perform a computer-based motor learning assessment at the baseline, 4-week, 8-week, and 6-month assessments. A retention task, which involves shorter versions of the initial tasks, will also be completed within 72 hours of the initial assessment (initial test and retention test).

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Motor Learning
Description: Participants will be asked to perform a computer-based motor learning assessment at the baseline, 4-week, 8-week, and 6-month assessments. A retention task, which involves shorter versions of the initial tasks, will also be completed within 72 hours of the initial assessment (initial test and retention test).
Study: NCT05850286

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-BCMA CAR-T
Description: Autologous BCMA-directed CAR-T cells, double infusion intravenously at a target dose of 2.0-4.0 x 10\^6 anti-BCMA CAR+T cells/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VRD-based Regimen
Description: Bortezomib, Lenalidomide and Dexamethasone
Study: NCT04717986

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: patients meeting the inclusion criteria will be randomized to receive a placebo solution every 24 hours for 12 months
Study: NCT05954117

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adipose tissue biopsies
Description: During the 2 surgical time, when patient is under general anesthesia, two adipose tissue biopsies of 20cc each (one from abdominal subcutaneous adipose tissue and one from omental adipose tissue) are taken and characterize by oxygraphy (respirometry).~Before the 2 surgical times (before and after chemotherapy) patients will have evaluation of the muscle strength, cachexia (by scan analysis), energy expenditure, anthropometric criteria and biochemical inflammatory.
Study: NCT05809219

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1 hour combined intervention ( Exercise and nutrition)
Description: Subjects take oral supplement after exercise in the time period between 1-2 hours. They will take oral supplement during hemodialysis treatment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3 hours combined intervention ( Exercise and nutrition)
Description: All procedures between 1 hour combined intervention and 3 hours combined intervention are the same. The only one different is the time interval between exercise and nutrition. In this arm, the time interval of exercise and nutrition is 2.5 to 4 hours. When we recruiting subjects, all interventions will be clearly introduced to them, including the same and the different parts among them.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutrition intervention
Description: Subjects only take oral supplement during hemodialysis treatment. The oral supplement is the same as the 1 hour combined intervention and 3 hours combined intervention.
Study: NCT05033769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin Injection [Halaven]
Description: on days 1 and 8 q21d

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel injection
Description: on days 1, 8, and 15 q21d
Study: NCT05669612

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dairy based protein
Description: Initial bioavailability trial, followed by 2 weeks consumption of product and follow up bioavailability trial

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mixed protein
Description: Initial bioavailability trial, followed by 2 weeks consumption of product and follow up bioavailability trial

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Plant-based protein 1
Description: Initial bioavailability trial, followed by 2 weeks consumption of product and follow up bioavailability trial

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Plant-based protein 2
Description: Initial bioavailability trial, followed by 2 weeks consumption of product and follow up bioavailability trial
Study: NCT05050461

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Immunological analyses
Description: Immunological analyses will be performed at inclusion in both arms

Intervention type: OTHER
Group type: OTHER
Intervention: Immunological analyses
Description: Immunological analyses will be performed at inclusion in both arms
Study: NCT06221033

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: manual hyperinflation
Description: Each participant will assume a relaxed comfortable in supine position. Bag valve resuscitation circuit locked at pressure 35 cm H20 will be used. Six sets of six MHI breaths will be applied. MHI breaths had a slow inspiration for three seconds duration, a three second end inspiratory pause (hold) then an uninterrupted expiration as a quick release

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diaphragmatic proprioceptive neuromuscular facilitation technique
Description: Rhythmic initiation technique that is derived from the PNF concept will be initiated by four 20-second manual diaphragm stimulations. After every stimulation the patient rested for one minute. Therapist's hands will be placed below the rib cage, just below the costal arches and will support patient's exhalation phase by slight lengthening his diaphragm simultaneously in posterior-superior direction using a verbal cue exhale. At the same time, the patient will verbally be encouraged to take a deep breath

Intervention type: OTHER
Group type: OTHER
Intervention: traditional physiotherapy
Description: This group will receive the traditional medical treatment and chest physiotherapy only.
Study: NCT05680922

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LB2102
Description: DLL3 directed autologous Chimeric Antigen Receptor T-cells
Study: NCT05674019

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI exam
Description: Brain MRI Morphometric exam

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MRI exam
Description: Brain MRI Morphometric exam
Study: NCT05275166

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Induction of alcohol craving
Description: Presentation of images that may induce craving for alcohol. Recording of brain activity

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Induction of alcohol craving
Description: Presentation of images that may induce craving for alcohol. Recording of brain activity

Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaires
Description: Questionnaires related to alcohol, quality of life, anxiety and depression

Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaires
Description: Questionnaires related to alcohol, quality of life, anxiety and depression
Study: NCT06498518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMM-101, Pembrolizumab, Gemcitabine
Description: Patients will receive IMM-101, Pembrolizumab, Gemcitabine on a 3 week cycle